close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

5.830 +0.540 (+10.21%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Pricing of Public Offering
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces $80 Million Proposed Public Offering
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Join Russell 3000® Index
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
By Jeremy Golden, Benzinga 
Via TheNewswire.com
News headline image
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC 
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
From Candel Therapeutics
Via GlobeNewswire
News headline image
Unusually High Volume Points to Upside in These Stocks
Unusually high volume is often a signal of higher price to come; this is a look at three stocks with recent volume spikes and a reason for the price to advance. 
Via MarketBeat
Topics ETFs
News headline image
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END 
Via FinancialNewsMedia
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today